Mental health and addiction recovery experts emphasize that relapse prevention requires a personalized, written plan combining trigger identification, coping strategies, and support systems. Recent ...

The FDA has approved Johnson & Johnson’s supplemental new drug application for Caplyta among patients with schizophrenia at ...

Drug addiction is a chronic, often relapsing disorder that affects millions of people worldwide. Despite successful treatment, many individuals struggle to maintain sobriety and may relapse.

Recovery from addiction is a challenging journey, filled with both triumphs and setbacks. For individuals seeking long-term sobriety, relapse can be a disheartening reality. However, recent findings ...

RIVERSIDE, Calif. – Resurgence Behavioral Health in Riverside announced the release of its latest educational article, “How Can You Use the Five Rules of Recovery to Stay Sober?”, offering practical ...

In today's ACT Brief, we examine governance inertia when AI accelerates protocol development, why payment experience is ...

This transcript has been edited for clarity. John Kane, MD: I am Dr John Kane. I am a professor of psychiatry at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell in Hempstead, New ...

Dr. Ellen Romich examines associated vasculitis relapse and which markers signal flare after stopping treatment.

New research highlights how AI-powered monitoring, digital therapeutics, and online recovery tools are transforming relapse prevention for addiction and mental health. Studies show these technologies ...

Researchers discover a paradox: high cognitive performance predicts depressive relapse, contradicting traditional expectations.

FDA label expansion adds relapse-prevention in adult schizophrenia, addressing a major driver of hospitalization, functional ...